NA-831 provides neuroprotection and catalyzes the regeneration of new neurons. Phase 2A clinical trials of NA-831 showed a proof of safety and efficacy for mild and moderate Alzheimer’s Disease.
Learn moreNA-901 shows promise as a treatment for Major Depressive Disorder. Results of a Phase 1B study have demonstrated a excellent safety profile with no adverse side effects. NA-901 is ready for Phase 2/3 for the treatment of MDD.
Learn moreNA-931 regulates the homeostasis of insulin-like growth factor (IGF-1) function and GLP-1 associated with diabetes obesity. NA-931 is a small molecule drug, available in an oral formulation. It can significantly reduce the body mass index, without causing muscle loss.
Learn moreNA-704 stimulates neurogenesis and reduce muscular spasticity, a candidate for ALS and Parkinson’s disease. NA-704 exhibits neuroprotection and it has great bioavailability in the body. NA-704 is in the Phase 2A clinical trials.
Learn moreNA-921™is a small molecule drug that is in Phase 2/3 clinical trials for the treatment of Rett Syndrome. NA-921 can easily crosses the blood brain barrier, so only a small dose of the drug is required to be effective.
Learn moreThe MICROS is a controlled release infusion system which has been approved for marketing in the US. It is used for intravenous administration of injectable drugs. NA-704 can be administered via the MICROS at home care settings. It is an accurate, safe and cost effective drug delivery system.
Learn more